Use of immune combinatorial diversity as a predictive marker for identifying patients likely to respond to an anti-CTLA-4 treatment

摘要

The present invention pertains to the field of cancer therapy and provides a predictive marker for determining if a patient suffering from metastatic melanoma or another cancer is likely to be a good responder to a treatment by Ipilimumab or another drug blocking an immune checkpoint.